Factors that predict incomplete virological response to protease inhibitor-based antiretroviral therapy

被引:27
作者
Clough, LA
D'Agata, E
Raffanti, S
Haas, DW
机构
[1] Vanderbilt Univ, Sch Med, Dept Med, Div Infect Dis, Nashville, TN 37212 USA
[2] Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37212 USA
[3] Comprehens Canc Ctr, Nashville, TN USA
关键词
D O I
10.1086/520185
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Many patients infected with human immunodeficiency virus type 1 (HIV-1) have suboptimal responses to protease inhibitor-based therapy. We retrospectively evaluated a cohort of 104 HIV-positive adults, most of whom had previously received antiretrovirals, to identify the frequency and clinical predictors of incomplete response to potent HIV-1 protease inhibitors. Sixty-two (60%) of the patients had an incomplete response, defined as a plasma HIV-1 RNA level of >400 copies/mL after 20 weeks of therapy. Logistic regression analysis identified the following independent risk factors for incomplete response: elevated baseline plasma HIV-1 RNA level (P = .03), low baseline weight (P = .01), chemoprophylaxis for Pneumocystis carinii pneumonia (P = .04), and active illicit drug use (P = .04), Regular prescription of narcotics or benzodiazepine anxiolytics (P = .01) and use of any Internet site (P = .01) predicted a more favorable response. Identifying factors that predict suboptimal response to protease inhibitors improves our understanding of interpatient variability in response to therapy and should foster strategies that enhance the effectiveness of current and future regimens.
引用
收藏
页码:75 / 81
页数:7
相关论文
共 24 条
[1]   IN-VIVO EMERGENCE OF HIV-1 VARIANTS RESISTANT TO MULTIPLE PROTEASE INHIBITORS [J].
CONDRA, JH ;
SCHLEIF, WA ;
BLAHY, OM ;
GABRYELSKI, LJ ;
GRAHAM, DJ ;
QUINTERO, JC ;
RHODES, A ;
ROBBINS, HL ;
ROTH, E ;
SHIVAPRAKASH, M ;
TITUS, D ;
YANG, T ;
TEPPLER, H ;
SQUIRES, KE ;
DEUTSCH, PJ ;
EMINI, EA .
NATURE, 1995, 374 (6522) :569-571
[2]   ZIDOVUDINE RESISTANCE AND HIV-1 DISEASE PROGRESSION DURING ANTIRETROVIRAL THERAPY [J].
DAQUILA, RT ;
JOHNSON, VA ;
WELLES, SL ;
JAPOUR, AJ ;
KURITZKES, DR ;
DEGRUTTOLA, V ;
REICHELDERFER, PS ;
COOMBS, RW ;
CRUMPACKER, CS ;
KAHN, JO ;
RICHMAN, DD .
ANNALS OF INTERNAL MEDICINE, 1995, 122 (06) :401-408
[3]  
DEEKS S, 1997, 37 C ANT AG CHEM TOR
[4]  
DEMETER L, 1998, 5 C RETR OPP INF WAS
[5]   HIV AND INTRAVENOUS DRUG-USE [J].
DESJARLAIS, DC ;
FRIEDMAN, SR .
AIDS, 1988, 2 :S65-S69
[6]   RETINOIDS ARE IMPORTANT COFACTORS IN T-CELL ACTIVATION [J].
GARBE, A ;
BUCK, J ;
HAMMERLING, U .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 176 (01) :109-117
[7]   Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy [J].
Gulick, RM ;
Mellors, JW ;
Havlir, D ;
Eron, JJ ;
Gonzalez, C ;
McMahon, D ;
Richman, DD ;
Valentine, FT ;
Jonas, L ;
Meibohm, A ;
Emini, EA ;
Chodakewitz, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) :734-739
[8]   A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less [J].
Hammer, SM ;
Squires, KE ;
Hughes, MD ;
Grimes, JM ;
Demeter, LM ;
Currier, JS ;
Eron, JJ ;
Feinberg, JE ;
Balfour, HH ;
Dayton, LR ;
Chodakewitz, JA ;
Fischl, MA .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) :725-733
[9]  
HAVLIR DV, 1998, 5 C RETR OPP INF WAS
[10]   Monitoring plasma HIV-1 RNA levels in addition to CD4(+) lymphocyte count improves assessment of antiretroviral therapeutic response [J].
Hughes, MD ;
Johnson, VA ;
Hirsch, MS ;
Bremer, JW ;
Elbeik, T ;
Erice, A ;
Kuritzkes, DR ;
Scott, WA ;
Spector, SA ;
Basgoz, N ;
Fischl, MA ;
DAquila, RT .
ANNALS OF INTERNAL MEDICINE, 1997, 126 (12) :929-938